Skip to main content

Market Overview

MediciNov Sees Volume After Zacks Research Raises Price Target To $28

Share:
MediciNov Sees Volume After Zacks Research Raises Price Target To $28
  • MediciNov Inc (NASDAQ: MNOV) sees a trading volume of 18.5 million shares after Zacks Small Cap Research increased the stock price target to $28 from $26.5 earlier.
  • The research notes positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) published in Translational Psychiatry.
  • While ibudilast did not significantly affect negative mood, it reduced the odds of heavy drinking across time by 45%, attenuated alcohol cue-elicited activation in the ventral striatum compared to placebo.
  • It also reduced alcohol craving compared to placebo on non-drinking days.
  • There were no significant differences between groups on any baseline characteristic, and overall medication compliance was high.
  • Price Action: During the mid-day session, the stock was trading 7.38% lower at $3.89 on the last check Tuesday.

Latest Ratings for MNOV

DateFirmActionFromTo
Mar 2021Maxim GroupInitiates Coverage OnBuy
Mar 2020B. Riley SecuritiesMaintainsBuy
Mar 2019B. Riley SecuritiesAssumesBuy

View More Analyst Ratings for MNOV
View the Latest Analyst Ratings

 

Related Articles (MNOV)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Penny Stocks Health Care Price Target Analyst Ratings General

Latest Ratings

StockFirmActionPT
RYCEYRedburn PartnersUpgrades
MMENCanaccord GenuityUpgrades0.400
VTEXMorgan StanleyUpgrades30.0
CRMRBC CapitalMaintains325.0
NKEB of A SecuritiesMaintains160.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com